As of 2025-10-19, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 91.52 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 14.6x | 13.4x |
| Forward P/E multiples | 17.1x - 35.5x | 20.4x |
| Fair Price | (8.61) - (7.36) | (8.52) |
| Upside | -369.0% - -329.9% | -366.2% |
| Date | EV/EBITDA |